Menu
Search
|

Menu

Close
X

Kamada Ltd KMDA.OQ (NASDAQ Stock Exchange Global Select Market)

5.25 USD
-0.05 (-0.94%)
As of Feb 16
chart
Previous Close 5.30
Open 5.30
Volume 1,697
3m Avg Volume 10,004
Today’s High 5.30
Today’s Low 5.25
52 Week High 8.55
52 Week Low 3.75
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Leon Recanati
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Amir London
Chief Executive Officer, Since 2015
Salary: --
Bonus: --
David Tsur
Deputy Chairman of the Board, Since 2015
Salary: 804,000.00₪
Bonus: 763,000.00₪
Chaime Orlev
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Ruth Wolfson
Senior Vice President - Scientific Affairs, Since 2015
Salary: 402,000.00₪
Bonus: 52,000.00₪

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2 Holtzman St., Science Park
REHOVOT     7670402

Phone: +9728.9406472

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

SPONSORED STORIES